

Socrates E Papapoulos

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8255338/socrates-e-papapoulos-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

11,143
citations

50
h-index

105
g-index

130
ext. papers

12,308
ext. citations

6.5
avg, IF

6.05
L-index

#	Paper	IF	Citations
127	Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1-23	6.3	935
126	Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2267-94	6.3	840
125	Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. <i>FASEB Journal</i> , 2005 , 19, 1842-4	0.9	709
124	Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. <i>Journal of Experimental Medicine</i> , 2004 , 199, 805-14	16.6	691
123	Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. <i>Osteoporosis International</i> , 1999 , 10, 259-64	5.3	517
122	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 513-523	18.1	419
121	Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 264, 108-11	3.4	414
120	SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. <i>Cytokine and Growth Factor Reviews</i> , 2005 , 16, 319-27	17.9	289
119	A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. <i>American Journal of Medical Genetics Part A</i> , 2002 , 110, 144-52		253
118	Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 694-701	6.3	235
117	Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 1996 , 39, 396-402		214
116	Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. <i>Bone</i> , 2010 , 47, 169-80	4.7	212
115	The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4483-92	5.6	202
114	Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 19-28	6.3	202
113	Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. <i>Medicine (United States)</i> , 1997 , 76, 266-83	1.8	196
112	The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 722-9	6.3	180
111	Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 551-70	6.2	171

110	Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 255, 491-4	3.4	170
109	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. <i>Bone</i> , 2008 , 42, 841-7	4.7	166
108	Pharmacology of bisphosphonates. <i>Bone</i> , 2011 , 49, 42-9	4.7	148
107	Prolonged bisphosphonate release after treatment in children. <i>New England Journal of Medicine</i> , 2007 , 356, 1075-6	59.2	147
106	Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. <i>Bone</i> , 2011 , 48, 966-71	4.7	145
105	Bone mineral density in sclerosteosis; affected individuals and gene carriers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 6392-5	5.6	140
104	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. <i>Nature Genetics</i> , 2011 , 43, 685-9	36.3	134
103	Interleukin-17: A new bone acting cytokine in vitro. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 1513-21	6.3	134
102	Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 956-62	6.3	122
101	Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1736-40	6.3	107
100	Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. <i>Osteoporosis International</i> , 2005 , 16, 468-74	5.3	107
99	Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 1077-91	6.3	107
98	Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2804-11	6.3	103
97	Structural requirements for bisphosphonate actions in vitro. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1875-82	6.3	100
96	ACTIVEExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2949-2957	5.6	90
95	Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 848-54	6.3	89
94	Bisphosphonates: how do they work?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 831-47	6.5	88
93	Inhibition of cathepsin K for treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2012 , 10, 73-9	5.4	81

92	A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3713-20	5.6	76
91	Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3873-83	5.6	75
90	Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. <i>Journal of Bone and Mineral Research</i> , 1996 , 11, 1492-7	6.3	72
89	Bisphosphonate actions: physical chemistry revisited. <i>Bone</i> , 2006 , 38, 613-6	4.7	66
88	Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 2220-2228	6.3	64
87	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 899-911	18.1	61
86	The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 2441-9	5.6	61
85	Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 1057-64	6.3	59
84	A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. <i>European Journal of Clinical Pharmacology</i> , 2002 , 57, 883-90	2.8	58
83	Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis. <i>Drugs</i> , 2015 , 75, 1049-58	12.1	56
82	Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. <i>European Journal of Endocrinology</i> , 2017 , 176, 677-683	6.5	54
81	Sclerostin Inhibition in the Management of Osteoporosis. <i>Calcified Tissue International</i> , 2016 , 98, 370-80	3.9	54
80	Sclerostin deficiency in humans. <i>Bone</i> , 2017 , 96, 51-62	4.7	54
79	Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 775-81	6.3	54
78	Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. <i>Laboratory Investigation</i> , 2001 , 81, 5-15	5.9	51
77	Targeting sclerostin as potential treatment of osteoporosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70 Suppl 1, i119-22	2.4	50
76	Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover. <i>Bone</i> , 2012 , 51, 153-7	4.7	49
75	The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. <i>Human Genetics</i> , 2010 , 128, 615-26	6.3	49

74	Paget [®] disease of bone in The Netherlands: a population-based radiological and biochemical survey—the Rotterdam Study. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 566-70	6.3	49
73	The role of bisphosphonates in the prevention and treatment of osteoporosis. <i>American Journal of Medicine</i> , 1993 , 95, 48S-52S	2.4	45
72	Sclerostin deficiency is linked to altered bone composition. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2144-51	6.3	44
71	First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. <i>Human Mutation</i> , 2010 , 31, E1526-43	4.7	44
70	Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton. <i>Cancer</i> , 2000 , 88, 3047-3053	6.4	44
69	Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 1543-7	6.3	41
68	Improved treatment of Paget [®] disease with dimethylaminohydroxypropylidene bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1993 , 8, 175-82	6.3	39
67	Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1021-8	6.3	38
66	Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget [®] disease of bone. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2592-605	6.3	36
65	IL-1alpha, IL-1beta, IL-6, and TNF-alpha steady-state mRNA levels analyzed by reverse transcription-competitive PCR in bone marrow of gonadectomized mice. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 185-94	6.3	36
64	SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. <i>Developmental Dynamics</i> , 2007 , 236, 606-12	2.9	36
63	In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 1523-30	6.3	34
62	Founder effect in different European countries for the recurrent P392L SQSTM1 mutation in Paget [®] Disease of Bone. <i>Calcified Tissue International</i> , 2008 , 83, 34-42	3.9	34
61	Paget [®] disease of bone: clinical, pathogenetic and therapeutic aspects. <i>Baillieres[®] Clinical Endocrinology and Metabolism</i> , 1997 , 11, 117-43		32
60	Selection of antiresorptive or anabolic treatments for postmenopausal osteoporosis. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008 , 4, 514-23		30
59	Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget [®] disease of bone. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 868-75	6.3	29
58	The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein. <i>Cancer</i> , 1991 , 68, 642-7	6.4	29
57	Paget [®] disease of bone. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018 , 32, 657-668	6.5	29

56	Glucocorticoids are not always deleterious for bone. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2796-800	6.3	26
55	Acquired resistance to bisphosphonates in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2006 , 21 Suppl 2, P88-91	6.3	26
54	Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 6069-6078	5.6	24
53	Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 69-70	15.2	24
52	Novel approaches to the treatment of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014 , 28, 843-57	6.5	24
51	Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. <i>Bone</i> , 2012 , 50, 1130-4	4.7	24
50	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2443-2452	5.6	23
49	Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 605-623	15.2	23
48	Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 981-6	6.3	22
47	Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 1203-10	6.3	21
46	From disease to treatment: from rare skeletal disorders to treatments for osteoporosis. <i>Endocrine</i> , 2016 , 52, 414-26	4	19
45	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1481-1485	6.3	17
44	Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. <i>Bone</i> , 2003 , 33, 831-8	4.7	17
43	Use of bisphosphonates in the management of postmenopausal osteoporosis. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1218, 15-32	6.5	16
42	No effect of rosuvastatin in the zoledronate-induced acute-phase response. <i>Calcified Tissue International</i> , 2011 , 88, 402-8	3.9	15
41	Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor. <i>Bone</i> , 2006 , 38, 167-71	4.7	15
40	Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH) ₂ Vitamin D ₃ Treatment. <i>PLoS ONE</i> , 2015 , 10, e0140986	3.7	14
39	The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. <i>Bone</i> , 2020 , 138, 115478	4.7	13

38	Bisphosphonate therapy in children with secondary osteoporosis. <i>Hormone Research in Paediatrics</i> , 2011 , 76 Suppl 1, 24-7	3.3	12
37	Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial. <i>Current Medical Research and Opinion</i> , 2019 , 35, 2097-2102	2.5	11
36	Impact Microindentation: Consistency of Serial Measurements and Alterations in Patients With Paget [®] Disease of the Tibia. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 2375-2380	6.3	11
35	Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 805-20	5.3	9
34	Impact microindentation assesses subperiosteal bone material properties in humans. <i>Bone</i> , 2020 , 131, 115110	4.7	9
33	Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments. <i>Bone</i> , 2018 , 111, 36-43	4.7	8
32	Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. <i>BMC Musculoskeletal Disorders</i> , 2017 , 18, 174	2.8	8
31	Low-energy fractures of the humeral shaft and bisphosphonate use. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1425-31	6.3	7
30	Pharmacological management of Paget [®] disease of bone. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002 , 1, 149-158	2.5	7
29	The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4155-e4162	5.6	6
28	Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004 , 31, 1732-7	4.1	6
27	Pamidronate: A model compound of the pharmacology of nitrogen-containing bisphosphonates; A Leiden historical perspective. <i>Bone</i> , 2020 , 134, 115244	4.7	5
26	SOST/Sclerostin: An Osteocyte-Derived Inhibitor of Bone Formation that Antagonizes Canonical Wnt Signaling 2008 , 139-152		5
25	Who will benefit from antiresorptive treatment (bisphosphonates)?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 965-73	5.3	5
24	Familial Paget [®] disease of bone: Long-term follow-up of unaffected relatives with and without Sequestosome 1 mutations. <i>Bone</i> , 2019 , 128, 115044	4.7	4
23	Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption. <i>Bone</i> , 2020 , 138, 115512	4.7	4
22	Bone: Romosozumab - getting there but not quite yet. <i>Nature Reviews Endocrinology</i> , 2016 , 12, 691-692	15.2	4
21	Inhibition of sclerostin in the management of osteoporosis: results of a phase 2 clinical trial meet expectations. <i>BoneKEy Reports</i> , 2014 , 3, 523		4

20	Chapter 49. Bisphosphonates for Postmenopausal Osteoporosis	237-241	4
19	Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2010 , 5, 711-722		4.1 3
18	Impact microindentation measurements correlate with cortical bone material properties measured by Fourier transform infrared imaging in humans. <i>Bone</i> , 2020 , 137, 115437		4.7 2
17	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1225-1234		6.3 2
16	Fracture Liaison Service	2018 , 405-411	2
15	Bisphosphonates for Postmenopausal Osteoporosis	412-419	2
14	Use of a rat model for the simultaneous assessment of pharmacokinetic and pharmacodynamic aspects of bisphosphonate treatment: application to the study of intravenous ¹⁴ C-labeled 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 241-6		6.3 1
13	Determinants of bone strength and clinical practice; effects of bisphosphonates. <i>Bone</i> , 2007 , 41, S3-S7		4.7 1
12	Management of malignancy-associated hypercalcemia. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2002 , 1, 65-76		2.5 1
11	Prevalence of FRAX risk factors and the osteoporosis treatment gap among women ≥70 years of age in routine primary care across 8 countries in Europe.. <i>Archives of Osteoporosis</i> , 2022 , 17, 20		2.9 0
10	Long-Term Efficacy and Safety of Treatments for Osteoporosis	2016 , 203-232	
9	Olav Bijvoet 1928-2014. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2527-8		6.3
8	Is a single infusion of zoledronic acid superior to risedronate for the treatment of Paget's disease?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006 , 2, 252-3		
7	Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy. <i>Bone</i> , 2003 , 33, 831-831		4.7
6	New Bone-Forming Agents	2019 , 85-93	
5	Circulating Sclerostin in Bone Sclerosing Disorders. <i>Exposure and Health</i> , 2016 , 1-18		8.8
4	Circulating Sclerostin in Bone Sclerosing Disorders. <i>Biomarkers in Disease</i> , 2017 , 221-237		
3	Treatment of Male Osteoporosis with Bisphosphonates	2010 , 667-679	

2 Adverse Effects of Drugs for Osteoporosis **2018**, 579-587

1 Future Therapies **2018**, 603-609